A meta-analysis pooling 13 randomized trials finds that adding immune checkpoint inhibitors does not significantly improve overall survival in unselected patients with advanced ovarian cancer. The analysis frames the negative efficacy signal as a challenge for broad biomarker-agnostic checkpoint strategies in this setting. While immunotherapy combinations can affect response endpoints in oncology, this synthesis emphasizes the absence of a survival advantage in the broader population studied. The result is particularly relevant for treatment sequencing discussions where efficacy signals may vary by histology, tumor immune microenvironment, and molecular context. For trial and development teams, the immediate takeaway is the need to tighten patient selection and identify predictive biomarkers rather than assuming uniform benefit. The study’s context is a market where ovarian cancer remains a high-need area for effective immunotherapy, but where clinical outcomes appear constrained without enrichment strategies.